Welcome to STN International! Enter x:x

LOGINID:ssspta1611sxp

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2		"Ask CAS" for self-help around the clock
NEWS 3	May 12	EXTEND option available in structure searching
NEWS 4	May 12	Polymer links for the POLYLINK command completed in REGISTRY
NEWS 5	May 27	New UPM (Update Code Maximum) field for more efficient patent SDIs in CAplus
NEWS 6	May 27	CAplus super roles and document types searchable in REGISTRY
NEWS 7	Jun 28	Additional enzyme-catalyzed reactions added to CASREACT
NEWS 8	Jun 28	ANTE, AQUALINE, BIOENG, CIVILENG, ENVIROENG, MECHENG, and WATER from CSA now available on STN(R)
NEWS 9	Jul 12	BEILSTEIN enhanced with new display and select options, resulting in a closer connection to BABS
NEWS 10	Jul 30	BEILSTEIN on STN workshop to be held August 24 in conjunction with the 228th ACS National Meeting
NEWS 11	AUG 02	IFIPAT/IFIUDB/IFICDB reloaded with new search and display fields
NEWS 12	AUG 02	CAplus and CA patent records enhanced with European and Japan Patent Office Classifications
NEWS 13	AUG 02	STN User Update to be held August 22 in conjunction with the 228th ACS National Meeting
NEWS 14	AUG 02	The Analysis Edition of STN Express with Discover! (Version 7.01 for Windows) now available
NEWS 15	AUG 04	Pricing for the Save Answers for SciFinder Wizard within STN Express with Discover! will change September 1, 2004

NEWS EXPRESS	JULY 30 CURRENT WINDOWS VERSION IS V7.01, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 11 AUGUST 2004
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 10:54:23 ON 18 AUG 2004

```
=> file reg
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     0.21       0.21

FILE 'REGISTRY' ENTERED AT 10:54:32 ON 18 AUG 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   17 AUG 2004  HIGHEST RN 727974-89-2
DICTIONARY FILE UPDATES:  17 AUG 2004  HIGHEST RN 727974-89-2

TSCA INFORMATION NOW CURRENT THROUGH MAY 21, 2004

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

Crossover limits have been increased.  See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more
information enter HELP PROP at an arrow prompt in the file or refer
to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=>
Uploading c:\program files\stnexp\queries\10736243.1

L1      STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1                STR
```




```
G1 CH,NH
```

Structure attributes must be viewed using STN Express query preparation.

```
=> s l1 sss full
FULL SEARCH INITIATED 10:55:00 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -    109 TO ITERATE

100.0% PROCESSED     109 ITERATIONS                              2 ANSWERS
SEARCH TIME: 00.00.01

L2            2 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                   ENTRY    SESSION
FULL ESTIMATED COST                               155.42     155.63

FILE 'CAPLUS' ENTERED AT 10:55:05 ON 18 AUG 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 18 Aug 2004  VOL 141 ISS 8
FILE LAST UPDATED: 17 Aug 2004  (20040817/ED)

  This file contains CAS Registry Numbers for easy and accurate
  substance identification.

=> s l2
L3            1 L2

=> d l3 fbib hitstr abs total

L3   ANSWER 1 OF 1  CAPLUS  COPYRIGHT 2004 ACS on STN
AN   2002:539677  CAPLUS
DN   137:109202
TI   Preparation of 4-aryl substituted indolinones as protein kinase signal
     transduction modulators for inhibiting abnormal cell proliferation
IN   Cui, Jingrong; Zhang, Ruofei; Shen, Hong; Chu, Ji Yu; Zhang, Fang-Jie;
     Koenig, Marcel; Do, Steven Huy; Li, Xiaoyuan; Wei, Chung Chen; Tang, Peng
     Cho
PA   USA
SO   PCT Int. Appl., 560 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
```

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002055517	A2	20020718	WO 2001-US48564	20011220
	WO 2002055517	A3	20020926		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
				US 2000-256479P	P 20001220
	US 2003069297	A1	20030410	US 2001-23488	20011220
	US 6677368	B2	20040113		
				US 2000-256479P	P 20001220
	EP 1349852	A2	20031008	EP 2001-997065	20011220
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
				US 2000-256479P	P 20001220
				WO 2001-US48564	W 20011220
	JP 2004518669	T2	20040624	JP 2002-556186	20011220
				US 2000-256479P	P 20001220
				WO 2001-US48564	W 20011220
	US 2004157909	A1	20040812	US 2003-736243	20031216
				US 2000-256479P	P 20001220
				US 2001-23488	A3 20011220

OS MARPAT 137:109202

IT **442559-47-9P 442559-48-0P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(target compound; preparation of (aryl)(pyrrolylmethylene)indolinones as protein kinase signal transduction modulators)

RN 442559-47-9 CAPLUS

CN 2H-Indol-2-one, 4-(2-fluorophenyl)-1,3-dihydro-3-[[4,5,6,7-tetrahydro-5-[2-(1-pyrrolidinyl)ethyl]-1H-indol-2-yl]methylene]-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 442559-48-0 CAPLUS
CN 2H-Indol-2-one, 4-(3-fluorophenyl)-1,3-dihydro-3-[[4,5,6,7-tetrahydro-5-[2-(1-pyrrolidinyl)ethyl]-1H-indol-2-yl]methylene]-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



GI



I



II

AB Title compds. I [R1 = (un)substituted aryl or heteroaryl; R2 = H, halo, alkyl, alkenyl, alkynyl, heterocyclyl, etc.; R3 = (un)substituted pyrrole or cycloalkenylpyrrole], as well as pharmaceutical compns. thereof, are prepared and disclosed as compds. capable of modulating protein kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation. Thus II, was prepared via condensation of 4-phenyl-1,3-dihydroindol-2-one with 5-formyl-2-methyl-4-[3-(4-methylpiperazin-1-yl)propyl]-1H-pyrrole-3-carboxylic acid Et ester. I were evaluated against eight specfic kinases, e.g., FGFR1, for which I possessed IC50 values (μM) of 0.0091-2.07. The present invention also relates to methods for treating protein kinase related disorders.

Welcome to STN International! Enter x:x

LOGINID:ssspta1611sxp

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2		"Ask CAS" for self-help around the clock
NEWS 3	May 12	EXTEND option available in structure searching
NEWS 4	May 12	Polymer links for the POLYLINK command completed in REGISTRY
NEWS 5	May 27	New UPM (Update Code Maximum) field for more efficient patent SDIs in CAplus
NEWS 6	May 27	CAplus super roles and document types searchable in REGISTRY
NEWS 7	Jun 28	Additional enzyme-catalyzed reactions added to CASREACT
NEWS 8	Jun 28	ANTE, AQUALINE, BIOENG, CIVILENG, ENVIROENG, MECHENG, and WATER from CSA now available on STN(R)
NEWS 9	Jul 12	BEILSTEIN enhanced with new display and select options, resulting in a closer connection to BABS
NEWS 10	Jul 30	BEILSTEIN on STN workshop to be held August 24 in conjunction with the 228th ACS National Meeting
NEWS 11	AUG 02	IFIPAT/IFIUDB/IFICDB reloaded with new search and display fields
NEWS 12	AUG 02	CAplus and CA patent records enhanced with European and Japan Patent Office Classifications
NEWS 13	AUG 02	STN User Update to be held August 22 in conjunction with the 228th ACS National Meeting
NEWS 14	AUG 02	The Analysis Edition of STN Express with Discover! (Version 7.01 for Windows) now available
NEWS 15	AUG 04	Pricing for the Save Answers for SciFinder Wizard within STN Express with Discover! will change September 1, 2004

NEWS EXPRESS	JULY 30 CURRENT WINDOWS VERSION IS V7.01, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 11 AUGUST 2004
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 11:17:05 ON 18 AUG 2004

```
=> fdile reg
FDILE IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=>
Uploading
THIS COMMAND NOT AVAILABLE IN THE CURRENT FILE
Do you want to switch to the Registry File?
Choice (Y/n):
Switching to the Registry File...
Some commands only work in certain files.  For example, the EXPAND
command can only be used to look at the index in a file which has an
index.  Enter "HELP COMMANDS" at an arrow prompt (=>) for a list of
commands which can be used in this file.

=> FILE REGISTRY

COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       0.42       0.42

FILE 'REGISTRY' ENTERED AT 11:18:13 ON 18 AUG 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   17 AUG 2004  HIGHEST RN 727974-89-2
DICTIONARY FILE UPDATES:  17 AUG 2004  HIGHEST RN 727974-89-2

TSCA INFORMATION NOW CURRENT THROUGH MAY 21, 2004

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

Crossover limits have been increased.  See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more
information enter HELP PROP at an arrow prompt in the file or refer
to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=>
Uploading c:\program files\stnexp\queries\10736243.2

L1      STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1              STR
```



G1 CH,NH

Structure attributes must be viewed using STN Express query preparation.

```
=> s l1 sss full
FULL SEARCH INITIATED 11:18:33 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -   3216 TO ITERATE

100.0% PROCESSED    3216 ITERATIONS                          498 ANSWERS
SEARCH TIME: 00.00.01

L2          498 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                 ENTRY    SESSION
FULL ESTIMATED COST                             155.42     155.84

FILE 'CAPLUS' ENTERED AT 11:18:39 ON 18 AUG 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 18 Aug 2004  VOL 141 ISS 8
FILE LAST UPDATED: 17 Aug 2004  (20040817/ED)
```

This file contains CAS Registry Numbers for easy and accurate substance identification.

```
=> s l2
L3            3 L2

=> d l3 fbib hitstr abs total

L3   ANSWER 1 OF 3  CAPLUS  COPYRIGHT 2004 ACS on STN
AN   2004:182368  CAPLUS
DN   140:229401
TI   Three hybrid assay system for isolating ligand-binding polypeptides and
     for isolating small mol. ligands
IN   Come, Jon H.; Becker, Frank; Kley, Nikolai A.; Reichel, Christoph
PA   USA
SO   U.S. Pat. Appl. Publ., 238 pp., Cont.-in-part of U.S. Ser. No. 91,177.
     CODEN: USXXCO
DT   Patent
LA   English
FAN.CNT 3
     PATENT NO.          KIND   DATE        APPLICATION NO.          DATE
     ---------------     ----   --------    --------------------     --------
PI   US 2004043388        A1    20040304    US 2002-234985           20020903
                                             US 2001-272932P     P    20010302
                                             US 2001-278233P     P    20010323
                                             US 2001-329437P     P    20011015
                                             US 2002-91177       A2   20020304
     US 2003165873        A1    20030904    US 2002-91177            20020304
                                             US 2001-272932P     P    20010302
                                             US 2001-278233P     P    20010323
                                             US 2001-329437P     P    20011015
PATENT FAMILY INFORMATION:
FAN  2002:696096
     PATENT NO.          KIND   DATE        APPLICATION NO.          DATE
     ---------------     ----   --------    --------------------     --------
PI   WO 2002070662        A2    20020912    WO 2002-US6677           20020304
     WO 2002070662        A3    20021227
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM,
             HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS,
             LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO,
             RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ,
             VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
             CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
             BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
                                             US 2001-272932P     P    20010302
                                             US 2001-278233P     P    20010323
                                             US 2001-329437P     P    20011015
     EP 1364212           A2    20031126    EP 2002-723332           20020304
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
                                             US 2001-272932P     P    20010302
                                             US 2001-278233P     P    20010323
                                             US 2001-329437P     P    20011015
                                             WO 2002-US6677      W    20020304
FAN  2003:319902
```

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003033499	A2	20030424	WO 2002-US33052	20021015
	WO 2003033499	A3	20030814		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
				US 2001-329437P	P 20011015
				US 2001-336962P	P 20011203
	EP 1446405	A2	20040818	EP 2002-797047	20021015
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
				US 2001-329437P	P 20011015
				US 2001-336962P	P 20011203
				WO 2002-US33052	W 20021015
	US 2003162797	A1	20030828	US 2002-321284	20021217
	US 6753329	B2	20040622		
				US 2001-336962P	P 20011203
				WO 2002-US33052	A1 20021015

IT **666838-05-7D**, conjugates
RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(three hybrid assay system for isolating ligand-binding polypeptides and for isolating small mol. ligands)

RN 666838-05-7 CAPLUS

CN 2H-Indol-2-one, 4-(3-aminophenyl)-1,3-dihydro-3-(1H-pyrrol-2-ylmethylene)-(9CI) (CA INDEX NAME)



AB The invention provides compns. and methods for isolating ligand-binding polypeptides for a user-specified ligand, and for isolating small mol. ligands for a user-specified target polypeptide using an improved class of hybrid ligand compds. Preparation of compds., e.g a methotrexate moiety linked by a polyethylene gycol moiety to dexamethasone, is described.

L3 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2002:539677 CAPLUS

DN 137:109202

TI Preparation of 4-aryl substituted indolinones as protein kinase signal

transduction modulators for inhibiting abnormal cell proliferation
IN Cui, Jingrong; Zhang, Ruofei; Shen, Hong; Chu, Ji Yu; Zhang, Fang-Jie; Koenig, Marcel; Do, Steven Huy; Li, Xiaoyuan; Wei, Chung Chen; Tang, Peng Cho
PA USA
SO PCT Int. Appl., 560 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002055517	A2	20020718	WO 2001-US48564	20011220
WO 2002055517	A3	20020926		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
			US 2000-256479P	P 20001220
US 2003069297	A1	20030410	US 2001-23488	20011220
US 6677368	B2	20040113		
			US 2000-256479P	P 20001220
EP 1349852	A2	20031008	EP 2001-997065	20011220
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
			US 2000-256479P	P 20001220
			WO 2001-US48564	W 20011220
JP 2004518669	T2	20040624	JP 2002-556186	20011220
			US 2000-256479P	P 20001220
			WO 2001-US48564	W 20011220
US 2004157909	A1	20040812	US 2003-736243	20031216
			US 2000-256479P	P 20001220
			US 2001-23488	A3 20011220

OS MARPAT 137:109202
IT **442563-63-5**
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of (aryl)(pyrrolylmethylene)indolinones as protein kinase signal transduction modulators)
RN 442563-63-5 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 5-[(Z)-[4-(3-fluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



IT 442558-03-4P 442558-04-5P 442558-05-6P
442558-06-7P 442558-07-8P 442558-08-9P
442558-09-0P 442558-10-3P 442558-11-4P
442558-12-5P 442558-13-6P 442558-14-7P
442558-15-8P 442558-16-9P 442558-17-0P
442558-18-1P 442558-19-2P 442558-20-5P
442558-21-6P 442558-22-7P 442558-23-8P
442558-24-9P 442558-25-0P 442558-26-1P
442558-27-2P 442558-28-3P 442558-29-4P
442558-30-7P 442558-31-8P 442558-32-9P
442558-33-0P 442558-34-1P 442558-35-2P
442558-36-3P 442558-37-4P 442558-38-5P
442558-39-6P 442558-40-9P 442558-41-0P
442558-42-1P 442558-43-2P 442558-44-3P
442558-45-4P 442558-46-5P 442558-47-6P
442558-48-7P 442558-49-8P 442558-50-1P
442558-51-2P 442558-52-3P 442558-53-4P
442558-54-5P 442558-55-6P 442558-56-7P
442558-57-8P 442558-58-9P 442558-59-0P
442558-60-3P 442558-61-4P 442558-62-5P
442558-63-6P 442558-64-7P 442558-65-8P
442558-66-9P 442558-67-0P 442558-68-1P
442558-69-2P 442558-70-5P 442558-71-6P
442558-72-7P 442558-73-8P 442558-74-9P
442558-75-0P 442558-76-1P 442558-77-2P
442558-78-3P 442558-79-4P 442558-80-7P
442558-81-8P 442558-82-9P 442558-83-0P
442558-84-1P 442558-85-2P 442558-86-3P
442558-87-4P 442558-88-5P 442558-89-6P
442558-90-9P 442558-91-0P 442558-92-1P
442558-93-2P 442558-94-3P 442558-95-4P
442558-96-5P 442558-97-6P 442558-98-7P
442558-99-8P 442559-00-4P 442559-01-5P
442559-02-6P 442559-03-7P 442559-04-8P
442559-05-9P 442559-06-0P 442559-07-1P
442559-08-2P 442559-09-3P 442559-10-6P
442559-11-7P 442559-12-8P 442559-14-0P
442559-15-1P 442559-16-2P 442559-19-5P
442559-20-8P 442559-21-9P 442559-22-0P
442559-23-1P 442559-24-2P 442559-25-3P
442559-26-4P 442559-27-5P 442559-28-6P
442559-29-7P 442559-30-0P 442559-31-1P
442559-32-2P 442559-41-3P 442559-42-4P
442559-43-5P 442559-44-6P 442559-45-7P
442559-46-8P 442559-47-9P 442559-48-0P

442559-49-1P 442559-50-4P 442559-51-5P
442559-52-6P 442559-53-7P 442559-54-8P
442559-55-9P 442559-56-0P 442559-57-1P
442559-58-2P 442559-59-3P 442559-60-6P
442559-61-7P 442559-62-8P 442559-63-9P
442559-64-0P 442559-65-1P 442559-66-2P
442559-67-3P 442559-68-4P 442559-69-5P
442559-70-8P 442559-71-9P 442559-72-0P
442559-73-1P 442559-74-2P 442559-75-3P
442559-76-4P 442559-77-5P 442559-78-6P
442559-79-7P 442559-80-0P 442559-81-1P
442559-82-2P 442559-83-3P 442559-84-4P
442559-85-5P 442559-86-6P 442559-87-7P
442559-88-8P 442559-89-9P 442559-90-2P
442559-91-3P 442559-92-4P 442559-93-5P
442559-94-6P 442559-95-7P 442559-96-8P
442559-97-9P 442559-98-0P 442559-99-1P
442560-00-1P 442560-01-2P 442560-02-3P
442560-03-4P 442560-04-5P 442560-05-6P
442560-06-7P 442560-07-8P 442560-08-9P
442560-09-0P 442560-10-3P 442560-11-4P
442560-12-5P 442560-13-6P 442560-14-7P
442560-15-8P 442560-16-9P 442560-17-0P
442560-18-1P 442560-19-2P 442560-20-5P
442560-21-6P 442560-22-7P 442560-23-8P
442560-24-9P 442560-25-0P 442560-26-1P
442560-27-2P 442560-28-3P 442560-29-4P
442560-30-7P 442560-31-8P 442560-32-9P
442560-33-0P 442560-34-1P 442560-35-2P
442560-36-3P 442560-37-4P 442560-38-5P
442560-39-6P 442560-40-9P 442560-41-0P
442560-42-1P 442560-43-2P 442560-44-3P
442560-45-4P 442560-46-5P 442560-47-6P
442560-48-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(target compound; preparation of (aryl)(pyrrolylmethylene)indolinones as protein kinase signal transduction modulators)

RN 442558-03-4 CAPLUS

CN 1H-Pyrrole-3-carboxylic acid, 5-[(1,2-dihydro-2-oxo-4-phenyl-3H-indol-3-ylidene)methyl]-2-methyl-4-[3-(4-methyl-1-piperazinyl)propyl]-, ethyl ester (9CI) (CA INDEX NAME)



AN 2000:421132 CAPLUS
DN 133:43433
TI Preparation of 4-aryl-3-(azolylmethylidene)-2-oxindoles as inhibitors of JNK protein kinases.
IN Corbett, Wendy Lea; Luk, Kin-chun; Mahaney, Paige E.
PA F. Hoffmann-La Roche A.-G., Switz.
SO PCT Int. Appl., 91 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2000035909	A1	20000622	WO 1999-EP9673	19991209

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,

Patel <8/18/2004>

DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

				US 1998-112590P	P	19981217
				US 1999-149028P	P	19990816
BR 9916223		A	20010904	BR 1999-16223		19991209
				US 1998-112590P	P	19981217
				US 1999-149028P	P	19990816
				WO 1999-EP9673	W	19991209
EP 1149093		A1	20011031	EP 1999-966933		19991209

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO

				US 1998-112590P	P	19981217
				US 1999-149028P	P	19990816
				WO 1999-EP9673	W	19991209
TR 200101858		T2	20011221	TR 2001-200101858		19991209
				US 1998-112590P	P	19981217
				US 1999-149028P	P	19990816
AU 760039		B2	20030508	AU 2000-22815		19991209
				US 1998-112590P	P	19981217
				US 1999-149028P	P	19990816
				WO 1999-EP9673	W	19991209
CN 1136216		B	20040128	CN 1999-814585		19991209
				US 1998-112590P	P	19981217
				US 1999-149028P	P	19990816
US 6307056		B1	20011023	US 1999-464466		19991215
				US 1998-112590P	P	19981217
				US 1999-149028P	P	19990816
ZA 2001004320		A	20020826	ZA 2001-4320		20010525
				US 1998-112590P	P	19981217

OS MARPAT 133:43433

IT **276250-95-4P 276250-97-6P 276250-98-7P**
276250-99-8P 276251-00-4P 276251-02-6P
276251-04-8P 276251-06-0P 276251-08-2P
276251-10-6P 276251-12-8P 276251-14-0P
276251-16-2P 276251-18-4P 276251-19-5P
276251-20-8P 276251-21-9P 276251-22-0P
276251-23-1P 276251-24-2P 276251-25-3P
276251-26-4P 276251-27-5P 276251-28-6P
276251-29-7P 276251-30-0P 276251-31-1P
276251-32-2P 276251-33-3P 276251-35-5P
276251-36-6P 276251-37-7P 276251-38-8P
276251-39-9P 276251-40-2P 276251-41-3P
276251-42-4P 276251-43-5P 276251-44-6P
276251-45-7P 276251-46-8P 276251-47-9P
276251-48-0P 276251-49-1P 276251-50-4P
276251-51-5P 276251-52-6P 276251-67-3P
276251-68-4P 276251-69-5P 276251-70-8P
276256-00-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 4-aryl-3-(azolylmethylidene)-2-oxindoles as inhibitors of JNK protein kinases)

RN 276250-95-4 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-4-phenyl-3-(1H-pyrrol-2-ylmethylene)-, (3Z)-(9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 276250-97-6 CAPLUS
CN 2H-Indol-2-one, 4-(3-aminophenyl)-1,3-dihydro-3-(1H-pyrrol-2-ylmethylene)-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 276250-98-7 CAPLUS
CN 2H-Indol-2-one, 4-(3-aminophenyl)-1,3-dihydro-3-(1H-pyrrol-2-ylmethylene)-, monohydrochloride, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



● HCl

RN 276250-99-8 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-4-(4-methoxyphenyl)-3-(1H-pyrrol-2-ylmethylene)-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 276251-00-4 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-4-(3-nitrophenyl)-3-(1H-pyrrol-2-ylmethylene)-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 276251-02-6 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-(1H-pyrrol-2-ylmethylene)-4-[3-(trifluoromethyl)phenyl]-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 276251-04-8 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-4-(4-methylphenyl)-3-(1H-pyrrol-2-ylmethylene)-

, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 276251-06-0 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-4-(2-methylphenyl)-3-(1H-pyrrol-2-ylmethylene)-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 276251-08-2 CAPLUS
CN 2H-Indol-2-one, 4-(2,4-dichlorophenyl)-1,3-dihydro-3-(1H-pyrrol-2-ylmethylene)-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 276251-10-6 CAPLUS
CN Methanesulfonamide, N-[3-[(3Z)-2,3-dihydro-2-oxo-3-(1H-pyrrol-2-ylmethylene)-1H-indol-4-yl]phenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 276251-12-8 CAPLUS
CN 2H-Indol-2-one, 4-(4-chlorophenyl)-1,3-dihydro-3-(1H-pyrrol-2-ylmethylene)-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 276251-14-0 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-4-(2-methoxyphenyl)-3-(1H-pyrrol-2-ylmethylene)-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 276251-16-2 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-4-(1-naphthalenyl)-3-(1H-pyrrol-2-ylmethylene)-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 276251-18-4 CAPLUS
CN 2-Thiophenesulfonamide, N-[3-[(3Z)-2,3-dihydro-2-oxo-3-(1H-pyrrol-2-ylmethylene)-1H-indol-4-yl]phenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 276251-19-5 CAPLUS
CN 2H-Indol-2-one, 4-(3-chlorophenyl)-1,3-dihydro-3-(1H-pyrrol-2-ylmethylene)-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 276251-20-8 CAPLUS
CN Benzoic acid, 4-[(3Z)-2,3-dihydro-2-oxo-3-(1H-pyrrol-2-ylmethylene)-1H-indol-4-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 276251-21-9 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-4-(4-hydroxyphenyl)-3-(1H-pyrrol-2-ylmethylene)-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 276251-22-0 CAPLUS

CN Benzamide, N-[3-[(3Z)-2,3-dihydro-2-oxo-3-(1H-pyrrol-2-ylmethylene)-1H-indol-4-yl]phenyl]-4-hydroxy- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 276251-23-1 CAPLUS
CN Benzamide, 3-bromo-N-[3-[(3Z)-2,3-dihydro-2-oxo-3-(1H-pyrrol-2-ylmethylene)-1H-indol-4-yl]phenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 276251-24-2 CAPLUS
CN Benzamide, 3-cyano-N-[3-[(3Z)-2,3-dihydro-2-oxo-3-(1H-pyrrol-2-ylmethylene)-1H-indol-4-yl]phenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 276251-25-3 CAPLUS
CN Benzamide, N-[3-[(3Z)-2,3-dihydro-2-oxo-3-(1H-pyrrol-2-ylmethylene)-1H-indol-4-yl]phenyl]-3-nitro- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 276251-26-4 CAPLUS
CN Benzamide, N-[3-[(3Z)-2,3-dihydro-2-oxo-3-(1H-pyrrol-2-ylmethylene)-1H-indol-4-yl]phenyl]-4-fluoro- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 276251-27-5 CAPLUS
CN Benzamide, N-[3-[(3Z)-2,3-dihydro-2-oxo-3-(1H-pyrrol-2-ylmethylene)-1H-indol-4-yl]phenyl]-4-nitro- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 276251-28-6 CAPLUS
CN Benzamide, N-[3-[(3Z)-2,3-dihydro-2-oxo-3-(1H-pyrrol-2-ylmethylene)-1H-indol-4-yl]phenyl]-4-methoxy- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 276251-29-7 CAPLUS
CN Benzenesulfonyl fluoride, 4-[[[3-[(3Z)-2,3-dihydro-2-oxo-3-(1H-pyrrol-2-ylmethylene)-1H-indol-4-yl]phenyl]amino]carbonyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 276251-30-0 CAPLUS
CN Benzoic acid, 3-[(3Z)-2,3-dihydro-2-oxo-3-(1H-pyrrol-2-ylmethylene)-1H-indol-4-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 276251-31-1 CAPLUS
CN Benzenesulfonyl fluoride, 4-[[[2-[[3-[(3Z)-2,3-dihydro-2-oxo-3-(1H-pyrrol-2-ylmethylene)-1H-indol-4-yl]phenyl]amino]-2-oxoethyl]amino]carbonyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 276251-32-2 CAPLUS
CN 2-Thiophenesulfonamide, N-[3-[(3Z)-2,3-dihydro-2-oxo-3-(1H-pyrrol-2-ylmethylene)-1H-indol-4-yl]phenyl]-4-(phenylsulfonyl)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 276251-33-3 CAPLUS
CN 2H-Indol-2-one, 4-(3-aminophenyl)-1,3-dihydro-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 276251-35-5 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-4-phenyl-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 276251-36-6 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-4-(4-hydroxyphenyl)-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 276251-37-7 CAPLUS
CN Benzoic acid, 4-[(3Z)-2,3-dihydro-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-2-oxo-1H-indol-4-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 276251-38-8 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-4-(4-hydroxyphenyl)-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-5-nitro-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 276251-39-9 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-5-nitro-4-phenyl-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 276251-40-2 CAPLUS
CN 2-Thiopheneacetamide, N-[(3Z)-2,3-dihydro-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-2-oxo-4-phenyl-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 276251-41-3 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-4-(1H-indol-5-yl)-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 276251-42-4 CAPLUS
CN 2H-Indol-2-one, 5-amino-1,3-dihydro-4-(4-hydroxyphenyl)-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 276251-43-5 CAPLUS
CN 2-Thiopheneacetamide, N-[(3Z)-2,3-dihydro-4-(4-hydroxyphenyl)-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-2-oxo-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 276251-44-6 CAPLUS
CN 2H-Indol-2-one, 5-amino-1,3-dihydro-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-4-phenyl-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 276251-45-7 CAPLUS
CN 2-Thiopheneacetamide, N-[(3Z)-2,3-dihydro-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-2-oxo[4,5'-bi-1H-indol]-5-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 276251-46-8 CAPLUS
CN Benzoic acid, 4-[(3Z)-2,3-dihydro-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-5-nitro-2-oxo-1H-indol-4-yl]-, methyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 276251-47-9 CAPLUS
CN Benzoic acid, 4-[(3Z)-5-amino-2,3-dihydro-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-2-oxo-1H-indol-4-yl]-, methyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 276251-48-0 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-4-(1H-indol-4-yl)-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 276251-49-1 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-4-(1H-indol-6-yl)-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 276251-50-4 CAPLUS
CN 2-Thiopheneacetamide, N-[(3Z)-2,3-dihydro-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-2-oxo[4,6'-bi-1H-indol]-5-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 276251-51-5 CAPLUS
CN Benzoic acid, 4-[(3Z)-2,3-dihydro-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-2-oxo-5-[(2-thienylacetyl)amino]-1H-indol-4-yl]-, methyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 276251-52-6 CAPLUS
CN Benzoic acid, 4-[(3Z)-2,3-dihydro-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-2-oxo-5-[(2-thienylacetyl)amino]-1H-indol-4-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 276251-67-3 CAPLUS
CN 2H-Indol-2-one, 5-fluoro-1,3-dihydro-4-(4-hydroxyphenyl)-3-[(3-methyl-1H-pyrrol-2-yl)methylene]-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 276251-68-4 CAPLUS
CN 2H-Indol-2-one, 5-fluoro-1,3-dihydro-4-(4-hydroxyphenyl)-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 276251-69-5 CAPLUS
CN Acetamide, 2-[[3-[(3Z)-5-fluoro-2,3-dihydro-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-2-oxo-1H-indol-4-yl]phenyl]amino]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 276251-70-8 CAPLUS
CN 2H-Indol-2-one, 5-fluoro-1,3-dihydro-4-[4-(hydroxymethyl)-3-methoxyphenyl]-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 276256-00-9 CAPLUS
CN Cyclohexanecarboxamide, 4-amino-N-[3-[(3Z)-2,3-dihydro-2-oxo-3-(1H-pyrrol-2-ylmethylene)-1H-indol-4-yl]phenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



IT **276251-76-4P 276251-79-7P 276251-80-0P**
276251-81-1P 276251-82-2P 276256-01-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of 4-aryl-3-(azolylmethylidene)-2-oxindoles as inhibitors of JNK protein kinases)
RN 276251-76-4 CAPLUS
CN Carbamic acid, [3-[(3Z)-2,3-dihydro-2-oxo-3-(1H-pyrrol-2-ylmethylene)-1H-indol-4-yl]phenyl]-, methyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 276251-79-7 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-4-(1H-indol-5-yl)-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-5-nitro-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 276251-80-0 CAPLUS
CN 2H-Indol-2-one, 5-amino-1,3-dihydro-4-(1H-indol-5-yl)-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 276251-81-1 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-4-(1H-indol-6-yl)-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-5-nitro-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 276251-82-2 CAPLUS
CN 2H-Indol-2-one, 5-amino-1,3-dihydro-4-(1H-indol-6-yl)-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 276256-01-0 CAPLUS
CN Carbamic acid, [4-[[[3-[(3Z)-2,3-dihydro-2-oxo-3-(1H-pyrrol-2-ylmethylene)-1H-indol-4-yl]phenyl]amino]carbonyl]cyclohexyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.



GI



I

AB Title compds. [I; A = (substituted) aryl, heteroaryl; R2 = H, halo, OR4, NR6R7, COR4, CO2R4, cyano, NO2, SO2R4, SO2NR6R7, etc.; R3 = H, OR4, COR4, CO2R4, CONR6R7, halo, cyano, NR6R7, perfluoroalkyl, (substituted) alkyl,

etc.; R4 = H, (substituted) alkyl, cycloalkyl, heterocyclyl; R6, R7 = H, (substituted) alkyl, cycloalkyl, COR8, CO2R8, SO2R8, etc.; NR6R7 = (substituted) 3-7 membered ring; R8 = H, (substituted) alkyl, aryl, heteroaryl, cycloalkyl; X = N, CH], were prepared Thus, (Z)-1,3-dihydro-4-iodo-3-[(1H-pyrrol-2-yl)methylene]-2H-indol-2-one (preparation given) was heated with phenylboronic acid, Pd(OAc)2, Et3N, and tri-O-tolylphosphine in DMF at 100° for 24 h to give 85% (Z)-1,3-dihydro-4-phenyl-3-[(1H-pyrrol-2-yl)methylene]-2H-indol-2-one. Tested I inhibited SAPK with IC50<0.15 μM.

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

			US 1998-112590P	P	19981217
			US 1999-149028P	P	19990816
BR 9916223	A	20010904	BR 1999-16223		19991209
			US 1998-112590P	P	19981217
			US 1999-149028P	P	19990816
			WO 1999-EP9673	W	19991209
EP 1149093	A1	20011031	EP 1999-966933		19991209
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO					
			US 1998-112590P	P	19981217
			US 1999-149028P	P	19990816
			WO 1999-EP9673	W	19991209
TR 200101858	T2	20011221	TR 2001-200101858		19991209
			US 1998-112590P	P	19981217
			US 1999-149028P	P	19990816
AU 760039	B2	20030508	AU 2000-22815		19991209
			US 1998-112590P	P	19981217
			US 1999-149028P	P	19990816
			WO 1999-EP9673	W	19991209
CN 1136216	B	20040128	CN 1999-814585		19991209
			US 1998-112590P	P	19981217
			US 1999-149028P	P	19990816
US 6307056	B1	20011023	US 1999-464466		19991215
			US 1998-112590P	P	19981217
			US 1999-149028P	P	19990816
ZA 2001004320	A	20020826	ZA 2001-4320		20010525
			US 1998-112590P	P	19981217

OS MARPAT 133:43433

IT **276250-95-4P 276250-97-6P 276250-98-7P**
276250-99-8P 276251-00-4P 276251-02-6P
276251-04-8P 276251-06-0P 276251-08-2P
276251-10-6P 276251-12-8P 276251-14-0P
276251-16-2P 276251-18-4P 276251-19-5P
276251-20-8P 276251-21-9P 276251-22-0P
276251-23-1P 276251-24-2P 276251-25-3P
276251-26-4P 276251-27-5P 276251-28-6P
276251-29-7P 276251-30-0P 276251-31-1P
276251-32-2P 276251-33-3P 276251-35-5P
276251-36-6P 276251-37-7P 276251-38-8P
276251-39-9P 276251-40-2P 276251-41-3P
276251-42-4P 276251-43-5P 276251-44-6P
276251-45-7P 276251-46-8P 276251-47-9P
276251-48-0P 276251-49-1P 276251-50-4P
276251-51-5P 276251-52-6P 276251-67-3P
276251-68-4P 276251-69-5P 276251-70-8P
276256-00-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 4-aryl-3-(azolylmethylidene)-2-oxindoles as inhibitors of JNK protein kinases)

RN 276250-95-4 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-4-phenyl-3-(1H-pyrrol-2-ylmethylene)-, (3Z)-(9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 276250-97-6 CAPLUS
CN 2H-Indol-2-one, 4-(3-aminophenyl)-1,3-dihydro-3-(1H-pyrrol-2-ylmethylene)-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 276250-98-7 CAPLUS
CN 2H-Indol-2-one, 4-(3-aminophenyl)-1,3-dihydro-3-(1H-pyrrol-2-ylmethylene)-, monohydrochloride, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



● HCl

RN 276250-99-8 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-4-(4-methoxyphenyl)-3-(1H-pyrrol-2-ylmethylene)-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 276251-00-4 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-4-(3-nitrophenyl)-3-(1H-pyrrol-2-ylmethylene)-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 276251-02-6 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-(1H-pyrrol-2-ylmethylene)-4-[3-(trifluoromethyl)phenyl]-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 276251-04-8 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-4-(4-methylphenyl)-3-(1H-pyrrol-2-ylmethylene)-

, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 276251-06-0 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-4-(2-methylphenyl)-3-(1H-pyrrol-2-ylmethylene)-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 276251-08-2 CAPLUS
CN 2H-Indol-2-one, 4-(2,4-dichlorophenyl)-1,3-dihydro-3-(1H-pyrrol-2-ylmethylene)-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 276251-10-6 CAPLUS
CN Methanesulfonamide,, N-[3-[(3Z)-2,3-dihydro-2-oxo-3-(1H-pyrrol-2-ylmethylene)-1H-indol-4-yl]phenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 276251-12-8 CAPLUS
CN 2H-Indol-2-one, 4-(4-chlorophenyl)-1,3-dihydro-3-(1H-pyrrol-2-ylmethylene)-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 276251-14-0 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-4-(2-methoxyphenyl)-3-(1H-pyrrol-2-ylmethylene)-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 276251-16-2 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-4-(1-naphthalenyl)-3-(1H-pyrrol-2-ylmethylene)-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 276251-18-4 CAPLUS
CN 2-Thiophenesulfonamide, N-[3-[(3Z)-2,3-dihydro-2-oxo-3-(1H-pyrrol-2-ylmethylene)-1H-indol-4-yl]phenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 276251-19-5 CAPLUS
CN 2H-Indol-2-one, 4-(3-chlorophenyl)-1,3-dihydro-3-(1H-pyrrol-2-ylmethylene)-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 276251-20-8 CAPLUS
CN Benzoic acid, 4-[(3Z)-2,3-dihydro-2-oxo-3-(1H-pyrrol-2-ylmethylene)-1H-indol-4-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 276251-21-9 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-4-(4-hydroxyphenyl)-3-(1H-pyrrol-2-ylmethylene)-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 276251-22-0 CAPLUS

CN Benzamide, N-[3-[(3Z)-2,3-dihydro-2-oxo-3-(1H-pyrrol-2-ylmethylene)-1H-indol-4-yl]phenyl]-4-hydroxy- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 276251-23-1 CAPLUS
CN Benzamide, 3-bromo-N-[3-[(3Z)-2,3-dihydro-2-oxo-3-(1H-pyrrol-2-ylmethylene)-1H-indol-4-yl]phenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 276251-24-2 CAPLUS
CN Benzamide, 3-cyano-N-[3-[(3Z)-2,3-dihydro-2-oxo-3-(1H-pyrrol-2-ylmethylene)-1H-indol-4-yl]phenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 276251-25-3 CAPLUS
CN Benzamide, N-[3-[(3Z)-2,3-dihydro-2-oxo-3-(1H-pyrrol-2-ylmethylene)-1H-indol-4-yl]phenyl]-3-nitro- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 276251-26-4 CAPLUS
CN Benzamide, N-[3-[(3Z)-2,3-dihydro-2-oxo-3-(1H-pyrrol-2-ylmethylene)-1H-indol-4-yl]phenyl]-4-fluoro- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 276251-27-5 CAPLUS
CN Benzamide, N-[3-[(3Z)-2,3-dihydro-2-oxo-3-(1H-pyrrol-2-ylmethylene)-1H-indol-4-yl]phenyl]-4-nitro- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 276251-28-6 CAPLUS
CN Benzamide, N-[3-[(3Z)-2,3-dihydro-2-oxo-3-(1H-pyrrol-2-ylmethylene)-1H-indol-4-yl]phenyl]-4-methoxy- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 276251-29-7 CAPLUS
CN Benzenesulfonyl fluoride, 4-[[[3-[(3Z)-2,3-dihydro-2-oxo-3-(1H-pyrrol-2-ylmethylene)-1H-indol-4-yl]phenyl]amino]carbonyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 276251-30-0 CAPLUS
CN Benzoic acid, 3-[(3Z)-2,3-dihydro-2-oxo-3-(1H-pyrrol-2-ylmethylene)-1H-indol-4-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 276251-31-1 CAPLUS
CN Benzenesulfonyl fluoride, 4-[[[2-[[3-[(3Z)-2,3-dihydro-2-oxo-3-(1H-pyrrol-2-ylmethylene)-1H-indol-4-yl]phenyl]amino]-2-oxoethyl]amino]carbonyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 276251-32-2 CAPLUS
CN 2-Thiophenesulfonamide, N-[3-[(3Z)-2,3-dihydro-2-oxo-3-(1H-pyrrol-2-ylmethylene)-1H-indol-4-yl]phenyl]-4-(phenylsulfonyl)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 276251-33-3 CAPLUS
CN 2H-Indol-2-one, 4-(3-aminophenyl)-1,3-dihydro-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 276251-35-5 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-4-phenyl-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 276251-36-6 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-4-(4-hydroxyphenyl)-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 276251-37-7 CAPLUS
CN Benzoic acid, 4-[(3Z)-2,3-dihydro-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-2-oxo-1H-indol-4-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 276251-38-8 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-4-(4-hydroxyphenyl)-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-5-nitro-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 276251-39-9 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-5-nitro-4-phenyl-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 276251-40-2 CAPLUS
CN 2-Thiopheneacetamide, N-[(3Z)-2,3-dihydro-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-2-oxo-4-phenyl-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 276251-41-3 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-4-(1H-indol-5-yl)-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 276251-42-4 CAPLUS
CN 2H-Indol-2-one, 5-amino-1,3-dihydro-4-(4-hydroxyphenyl)-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 276251-43-5 CAPLUS
CN 2-Thiopheneacetamide, N-[(3Z)-2,3-dihydro-4-(4-hydroxyphenyl)-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-2-oxo-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 276251-44-6 CAPLUS
CN 2H-Indol-2-one, 5-amino-1,3-dihydro-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-4-phenyl-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 276251-45-7 CAPLUS
CN 2-Thiopheneacetamide, N-[(3Z)-2,3-dihydro-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-2-oxo[4,5'-bi-1H-indol]-5-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 276251-46-8 CAPLUS
CN Benzoic acid, 4-[(3Z)-2,3-dihydro-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-5-nitro-2-oxo-1H-indol-4-yl]-, methyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 276251-47-9 CAPLUS
CN Benzoic acid, 4-[(3Z)-5-amino-2,3-dihydro-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-2-oxo-1H-indol-4-yl]-, methyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 276251-48-0 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-4-(1H-indol-4-yl)-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 276251-49-1 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-4-(1H-indol-6-yl)-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 276251-50-4 CAPLUS
CN 2-Thiopheneacetamide, N-[(3Z)-2,3-dihydro-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-2-oxo[4,6'-bi-1H-indol]-5-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 276251-51-5 CAPLUS
CN Benzoic acid, 4-[(3Z)-2,3-dihydro-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-2-oxo-5-[(2-thienylacetyl)amino]-1H-indol-4-yl]-, methyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 276251-52-6 CAPLUS
CN Benzoic acid, 4-[(3Z)-2,3-dihydro-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-2-oxo-5-[(2-thienylacetyl)amino]-1H-indol-4-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 276251-67-3 CAPLUS
CN 2H-Indol-2-one, 5-fluoro-1,3-dihydro-4-(4-hydroxyphenyl)-3-[(3-methyl-1H-pyrrol-2-yl)methylene]-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 276251-68-4 CAPLUS
CN 2H-Indol-2-one, 5-fluoro-1,3-dihydro-4-(4-hydroxyphenyl)-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 276251-69-5 CAPLUS
CN Acetamide, 2-[[3-[(3Z)-5-fluoro-2,3-dihydro-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-2-oxo-1H-indol-4-yl]phenyl]amino]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 276251-70-8 CAPLUS
CN 2H-Indol-2-one, 5-fluoro-1,3-dihydro-4-[4-(hydroxymethyl)-3-methoxyphenyl]-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 276256-00-9 CAPLUS
CN Cyclohexanecarboxamide, 4-amino-N-[3-[(3Z)-2,3-dihydro-2-oxo-3-(1H-pyrrol-2-ylmethylene)-1H-indol-4-yl]phenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



IT **276251-76-4P 276251-79-7P 276251-80-0P**
276251-81-1P 276251-82-2P 276256-01-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of 4-aryl-3-(azolylmethylidene)-2-oxindoles as inhibitors of JNK protein kinases)
RN 276251-76-4 CAPLUS
CN Carbamic acid, [3-[(3Z)-2,3-dihydro-2-oxo-3-(1H-pyrrol-2-ylmethylene)-1H-indol-4-yl]phenyl]-, methyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 276251-79-7 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-4-(1H-indol-5-yl)-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-5-nitro-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 276251-80-0 CAPLUS
CN 2H-Indol-2-one, 5-amino-1,3-dihydro-4-(1H-indol-5-yl)-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 276251-81-1 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-4-(1H-indol-6-yl)-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-5-nitro-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 276251-82-2 CAPLUS
CN 2H-Indol-2-one, 5-amino-1,3-dihydro-4-(1H-indol-6-yl)-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 276256-01-0 CAPLUS
CN Carbamic acid, [4-[[[3-[(3Z)-2,3-dihydro-2-oxo-3-(1H-pyrrol-2-ylmethylene)-1H-indol-4-yl]phenyl]amino]carbonyl]cyclohexyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.



GI



I

AB Title compds. [I; A = (substituted) aryl, heteroaryl; R2 = H, halo, OR4, NR6R7, COR4, CO2R4, cyano, NO2, SO2R4, SO2NR6R7, etc.; R3 = H, OR4, COR4, CO2R4, CONR6R7, halo, cyano, NR6R7, perfluoroalkyl, (substituted) alkyl,

etc.; R4 = H, (substituted) alkyl, cycloalkyl, heterocyclyl; R6, R7 = H, (substituted) alkyl, cycloalkyl, COR8, CO2R8, SO2R8, etc.; NR6R7 = (substituted) 3-7 membered ring; R8 = H, (substituted) alkyl, aryl, heteroaryl, cycloalkyl; X = N, CH], were prepared Thus, (Z)-1,3-dihydro-4-iodo-3-[(1H-pyrrol-2-yl)methylene]-2H-indol-2-one (preparation given) was heated with phenylboronic acid, Pd(OAc)2, Et3N, and tri-O-tolylphosphine in DMF at 100° for 24 h to give 85% (Z)-1,3-dihydro-4-phenyl-3-[(1H-pyrrol-2-yl)methylene]-2H-indol-2-one. Tested I inhibited SAPK with IC50<0.15 μM.

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

				US 1998-112590P	P	19981217
				US 1999-149028P	P	19990816
BR 9916223	A	20010904	BR 1999-16223			19991209
				US 1998-112590P	P	19981217
				US 1999-149028P	P	19990816
				WO 1999-EP9673	W	19991209
EP 1149093	A1	20011031	EP 1999-966933			19991209
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO						
				US 1998-112590P	P	19981217
				US 1999-149028P	P	19990816
				WO 1999-EP9673	W	19991209
TR 200101858	T2	20011221	TR 2001-200101858			19991209
				US 1998-112590P	P	19981217
				US 1999-149028P	P	19990816
AU 760039	B2	20030508	AU 2000-22815			19991209
				US 1998-112590P	P	19981217
				US 1999-149028P	P	19990816
				WO 1999-EP9673	W	19991209
CN 1136216	B	20040128	CN 1999-814585			19991209
				US 1998-112590P	P	19981217
				US 1999-149028P	P	19990816
US 6307056	B1	20011023	US 1999-464466			19991215
				US 1998-112590P	P	19981217
				US 1999-149028P	P	19990816
ZA 2001004320	A	20020826	ZA 2001-4320			20010525
				US 1998-112590P	P	19981217

OS MARPAT 133:43433

IT **276250-95-4P 276250-97-6P 276250-98-7P**
276250-99-8P 276251-00-4P 276251-02-6P
276251-04-8P 276251-06-0P 276251-08-2P
276251-10-6P 276251-12-8P 276251-14-0P
276251-16-2P 276251-18-4P 276251-19-5P
276251-20-8P 276251-21-9P 276251-22-0P
276251-23-1P 276251-24-2P 276251-25-3P
276251-26-4P 276251-27-5P 276251-28-6P
276251-29-7P 276251-30-0P 276251-31-1P
276251-32-2P 276251-33-3P 276251-35-5P
276251-36-6P 276251-37-7P 276251-38-8P
276251-39-9P 276251-40-2P 276251-41-3P
276251-42-4P 276251-43-5P 276251-44-6P
276251-45-7P 276251-46-8P 276251-47-9P
276251-48-0P 276251-49-1P 276251-50-4P
276251-51-5P 276251-52-6P 276251-67-3P
276251-68-4P 276251-69-5P 276251-70-8P
276256-00-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 4-aryl-3-(azolylmethylidene)-2-oxindoles as inhibitors of JNK protein kinases)

RN 276250-95-4 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-4-phenyl-3-(1H-pyrrol-2-ylmethylene)-, (3Z)-(9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 276250-97-6 CAPLUS
CN 2H-Indol-2-one, 4-(3-aminophenyl)-1,3-dihydro-3-(1H-pyrrol-2-ylmethylene)-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 276250-98-7 CAPLUS
CN 2H-Indol-2-one, 4-(3-aminophenyl)-1,3-dihydro-3-(1H-pyrrol-2-ylmethylene)-, monohydrochloride, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



● HCl

RN 276250-99-8 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-4-(4-methoxyphenyl)-3-(1H-pyrrol-2-ylmethylene)-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 276251-00-4 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-4-(3-nitrophenyl)-3-(1H-pyrrol-2-ylmethylene)-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 276251-02-6 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-(1H-pyrrol-2-ylmethylene)-4-[3-(trifluoromethyl)phenyl]-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 276251-04-8 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-4-(4-methylphenyl)-3-(1H-pyrrol-2-ylmethylene)-

, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 276251-06-0 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-4-(2-methylphenyl)-3-(1H-pyrrol-2-ylmethylene)-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 276251-08-2 CAPLUS
CN 2H-Indol-2-one, 4-(2,4-dichlorophenyl)-1,3-dihydro-3-(1H-pyrrol-2-ylmethylene)-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 276251-10-6 CAPLUS
CN Methanesulfonamide, N-[3-[(3Z)-2,3-dihydro-2-oxo-3-(1H-pyrrol-2-ylmethylene)-1H-indol-4-yl]phenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 276251-12-8 CAPLUS
CN 2H-Indol-2-one, 4-(4-chlorophenyl)-1,3-dihydro-3-(1H-pyrrol-2-ylmethylene)-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 276251-14-0 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-4-(2-methoxyphenyl)-3-(1H-pyrrol-2-ylmethylene)-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 276251-16-2 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-4-(1-naphthalenyl)-3-(1H-pyrrol-2-ylmethylene)-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 276251-18-4 CAPLUS
CN 2-Thiophenesulfonamide, N-[3-[(3Z)-2,3-dihydro-2-oxo-3-(1H-pyrrol-2-ylmethylene)-1H-indol-4-yl]phenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 276251-19-5 CAPLUS
CN 2H-Indol-2-one, 4-(3-chlorophenyl)-1,3-dihydro-3-(1H-pyrrol-2-ylmethylene)-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 276251-20-8 CAPLUS
CN Benzoic acid, 4-[(3Z)-2,3-dihydro-2-oxo-3-(1H-pyrrol-2-ylmethylene)-1H-indol-4-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 276251-21-9 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-4-(4-hydroxyphenyl)-3-(1H-pyrrol-2-ylmethylene)-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 276251-22-0 CAPLUS

CN Benzamide, N-[3-[(3Z)-2,3-dihydro-2-oxo-3-(1H-pyrrol-2-ylmethylene)-1H-indol-4-yl]phenyl]-4-hydroxy- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 276251-23-1 CAPLUS
CN Benzamide, 3-bromo-N-[3-[(3Z)-2,3-dihydro-2-oxo-3-(1H-pyrrol-2-ylmethylene)-1H-indol-4-yl]phenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 276251-24-2 CAPLUS
CN Benzamide, 3-cyano-N-[3-[(3Z)-2,3-dihydro-2-oxo-3-(1H-pyrrol-2-ylmethylene)-1H-indol-4-yl]phenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 276251-25-3 CAPLUS
CN Benzamide, N-[3-[(3Z)-2,3-dihydro-2-oxo-3-(1H-pyrrol-2-ylmethylene)-1H-indol-4-yl]phenyl]-3-nitro- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 276251-26-4 CAPLUS
CN Benzamide, N-[3-[(3Z)-2,3-dihydro-2-oxo-3-(1H-pyrrol-2-ylmethylene)-1H-indol-4-yl]phenyl]-4-fluoro- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 276251-27-5 CAPLUS
CN Benzamide, N-[3-[(3Z)-2,3-dihydro-2-oxo-3-(1H-pyrrol-2-ylmethylene)-1H-indol-4-yl]phenyl]-4-nitro- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 276251-28-6 CAPLUS
CN Benzamide, N-[3-[(3Z)-2,3-dihydro-2-oxo-3-(1H-pyrrol-2-ylmethylene)-1H-indol-4-yl]phenyl]-4-methoxy- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 276251-29-7 CAPLUS
CN Benzenesulfonyl fluoride, 4-[[[3-[(3Z)-2,3-dihydro-2-oxo-3-(1H-pyrrol-2-ylmethylene)-1H-indol-4-yl]phenyl]amino]carbonyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 276251-30-0 CAPLUS
CN Benzoic acid, 3-[(3Z)-2,3-dihydro-2-oxo-3-(1H-pyrrol-2-ylmethylene)-1H-indol-4-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 276251-31-1 CAPLUS
CN Benzenesulfonyl fluoride, 4-[[[2-[[3-[(3Z)-2,3-dihydro-2-oxo-3-(1H-pyrrol-2-ylmethylene)-1H-indol-4-yl]phenyl]amino]-2-oxoethyl]amino]carbonyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 276251-32-2 CAPLUS
CN 2-Thiophenesulfonamide, N-[3-[(3Z)-2,3-dihydro-2-oxo-3-(1H-pyrrol-2-ylmethylene)-1H-indol-4-yl]phenyl]-4-(phenylsulfonyl)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 276251-33-3 CAPLUS
CN 2H-Indol-2-one, 4-(3-aminophenyl)-1,3-dihydro-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 276251-35-5 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-4-phenyl-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 276251-36-6 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-4-(4-hydroxyphenyl)-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 276251-37-7 CAPLUS
CN Benzoic acid, 4-[(3Z)-2,3-dihydro-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-2-oxo-1H-indol-4-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 276251-38-8 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-4-(4-hydroxyphenyl)-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-5-nitro-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 276251-39-9 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-5-nitro-4-phenyl-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 276251-40-2 CAPLUS
CN 2-Thiopheneacetamide, N-[(3Z)-2,3-dihydro-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-2-oxo-4-phenyl-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 276251-41-3 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-4-(1H-indol-5-yl)-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 276251-42-4 CAPLUS
CN 2H-Indol-2-one, 5-amino-1,3-dihydro-4-(4-hydroxyphenyl)-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 276251-43-5 CAPLUS
CN 2-Thiopheneacetamide, N-[(3Z)-2,3-dihydro-4-(4-hydroxyphenyl)-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-2-oxo-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 276251-44-6 CAPLUS
CN 2H-Indol-2-one, 5-amino-1,3-dihydro-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-4-phenyl-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 276251-45-7 CAPLUS
CN 2-Thiopheneacetamide, N-[(3Z)-2,3-dihydro-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-2-oxo[4,5'-bi-1H-indol]-5-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 276251-46-8 CAPLUS
CN Benzoic acid, 4-[(3Z)-2,3-dihydro-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-5-nitro-2-oxo-1H-indol-4-yl]-, methyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 276251-47-9 CAPLUS
CN Benzoic acid, 4-[(3Z)-5-amino-2,3-dihydro-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-2-oxo-1H-indol-4-yl]-, methyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 276251-48-0 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-4-(1H-indol-4-yl)-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 276251-49-1 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-4-(1H-indol-6-yl)-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 276251-50-4 CAPLUS
CN 2-Thiopheneacetamide, N-[(3Z)-2,3-dihydro-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-2-oxo[4,6'-bi-1H-indol]-5-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 276251-51-5 CAPLUS
CN Benzoic acid, 4-[(3Z)-2,3-dihydro-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-2-oxo-5-[(2-thienylacetyl)amino]-1H-indol-4-yl]-, methyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 276251-52-6 CAPLUS
CN Benzoic acid, 4-[(3Z)-2,3-dihydro-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-2-oxo-5-[(2-thienylacetyl)amino]-1H-indol-4-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 276251-67-3 CAPLUS
CN 2H-Indol-2-one, 5-fluoro-1,3-dihydro-4-(4-hydroxyphenyl)-3-[(3-methyl-1H-pyrrol-2-yl)methylene]-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 276251-68-4 CAPLUS
CN 2H-Indol-2-one, 5-fluoro-1,3-dihydro-4-(4-hydroxyphenyl)-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 276251-69-5 CAPLUS
CN Acetamide, 2-[[3-[(3Z)-5-fluoro-2,3-dihydro-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-2-oxo-1H-indol-4-yl]phenyl]amino]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 276251-70-8 CAPLUS
CN 2H-Indol-2-one, 5-fluoro-1,3-dihydro-4-[4-(hydroxymethyl)-3-methoxyphenyl]-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 276256-00-9 CAPLUS
CN Cyclohexanecarboxamide, 4-amino-N-[3-[(3Z)-2,3-dihydro-2-oxo-3-(1H-pyrrol-2-ylmethylene)-1H-indol-4-yl]phenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



IT **276251-76-4P 276251-79-7P 276251-80-0P**
276251-81-1P 276251-82-2P 276256-01-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of 4-aryl-3-(azolylmethylidene)-2-oxindoles as inhibitors of JNK protein kinases)
RN 276251-76-4 CAPLUS
CN Carbamic acid, [3-[(3Z)-2,3-dihydro-2-oxo-3-(1H-pyrrol-2-ylmethylene)-1H-indol-4-yl]phenyl]-, methyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 276251-79-7 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-4-(1H-indol-5-yl)-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-5-nitro-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 276251-80-0 CAPLUS
CN 2H-Indol-2-one, 5-amino-1,3-dihydro-4-(1H-indol-5-yl)-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 276251-81-1 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-4-(1H-indol-6-yl)-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-5-nitro-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 276251-82-2 CAPLUS
CN 2H-Indol-2-one, 5-amino-1,3-dihydro-4-(1H-indol-6-yl)-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 276256-01-0 CAPLUS
CN Carbamic acid, [4-[[[3-[(3Z)-2,3-dihydro-2-oxo-3-(1H-pyrrol-2-ylmethylene)-1H-indol-4-yl]phenyl]amino]carbonyl]cyclohexyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.



GI



I

AB Title compds. [I; A = (substituted) aryl, heteroaryl; R2 = H, halo, OR4, NR6R7, COR4, CO2R4, cyano, NO2, SO2R4, SO2NR6R7, etc.; R3 = H, OR4, COR4, CO2R4, CONR6R7, halo, cyano, NR6R7, perfluoroalkyl, (substituted) alkyl,

etc.; R4 = H, (substituted) alkyl, cycloalkyl, heterocyclyl; R6, R7 = H, (substituted) alkyl, cycloalkyl, COR8, CO2R8, SO2R8, etc.; NR6R7 = (substituted) 3-7 membered ring; R8 = H, (substituted) alkyl, aryl, heteroaryl, cycloalkyl; X = N, CH], were prepared Thus, (Z)-1,3-dihydro-4-iodo-3-[(1H-pyrrol-2-yl)methylene]-2H-indol-2-one (preparation given) was heated with phenylboronic acid, Pd(OAc)2, Et3N, and tri-O-tolylphosphine in DMF at 100° for 24 h to give 85% (Z)-1,3-dihydro-4-phenyl-3-[(1H-pyrrol-2-yl)methylene]-2H-indol-2-one. Tested I inhibited SAPK with IC50<0.15 μM.

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT